The research revealed that two biomarkers, including FGF23 and brain natriuretic peptide (BNP) as well as assessment of three clinical risk factors: age, sex, and body mass index, may unambiguously identify patients with AF. This evidence concerns the gene FGF23 and atrial fibrillation.